Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of Tumor Treating Fields TTFields given with pembrolizumab and platinum-based chemotherapy in patients with advanced non-small cell lung cancer NSCLC that has spread to other parts of the body. This study, called LUNAR-2, compares this combination to pembrolizumab and chemotherapy alone, focusing on overall survival and progression-free survival. It also examines outcomes based on the specific subtype of lung cancer and PD-L1 expression levels. Participants receive either the combination of TTFields delivered by the portable NovoTTF-200T device, pembrolizumab, and platinum-based chemotherapy, or pembrolizumab and chemotherapy without TTFields. The NovoTTF-200T device delivers electric fields to disrupt cancer cell division and is used continuously at home. Treatments are given according to a randomized, open-label design. During the study, participants will be monitored regularly with evaluations of survival and disease progression for up to six years. Researchers will track response rates, duration of response, disease control, and adverse events. Assessments include measuring cancer status by standardized criteria. This long-term follow-up helps understand the effects and safety of the treatments over time.
Actively Recruiting
Researchers are evaluating the effects of etripamil nasal spray NS compared to placebo in patients who have atrial fibrillation AF with rapid ventricular rate RVR. This is a multi-national, multi-center, randomized, double-blind, placebo-controlled phase 3 study aiming to assess how well etripamil works in this condition. The study includes several phases such as screening, randomization, treatment, follow-up visits, a final study visit, and a telephone follow-up at the end. Participants are randomly assigned to receive either placebo or 70 mg of etripamil NS. They will self-administer the study drug during episodes of AF with RVR, starting with an initial dose and possibly a second dose 10 minutes later if symptoms continue. Patients may treat up to four episodes during the study. The study drug is given as a nasal spray, and the placebo formulation is designed to match the pH of the active drug. Participants will be involved in screening procedures including physical exams, vital signs, ECGs, and lab tests. During the treatment period, they will use ECG cardiac monitoring devices and report symptoms electronically. Monthly follow-up visits and post-treatment visits will monitor safety, collect information on any additional medical interventions, and ensure ongoing eligibility. The final study visit and a telephone follow-up approximately 30 days later will complete the study monitoring. The primary outcome is to measure the efficacy of etripamil within 30 minutes of the first dose.